DCTH

#3212
Delcath Systems Inc
10.8600 USD
+0.28%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
10.8600
10.8600
Year Range
8.1200
11.1500
Daily Change
+0.28%
Monthly Change
+12.66%
6 month change
+5.03%
Year Change
+5.03%
Previous Close
10.8300
Open
10.8600
Bid
Ask
Low
10.8600
High
10.8600
Volume
65
Open full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 377.3436 M
  • Employee 156
  • Founded 1988
  • CEO Gerard Michel
  • Website www.delcath.com
  • Headquarter Delaware, United States
  • FIGI BBG000BY2VF5
  • Industry Medical Devices
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
144.29
Price to sales ratio
4.73

Delcath Systems Inc

Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally.

News